

PEDONCOVID - SFCE national cohort on SARS-CoV-2 (COVID-19) infections in paediatric oncology-haematology

Responsable(s) : ROUGER-GAUDICHON Jérémie

Date de modification : 05/05/2021 | Version : 1 | ID : 73865

Général

Identification

Nom détaillé SFCE national cohort on SARS-CoV-2 (COVID-19) infections in paediatric oncology-haematology

Sigle ou acronyme PEDONCOVID

Thématiques générales

Domaine médical Pediatrics

Etude en lien avec la Covid-19 Yes

Pathologie, précisions Paediatric oncology

Mots-clés cancer; paediatrics; chemotherapy; SARS-CoV-2; COVID-19

Responsable(s) scientifique(s)

Nom du responsable ROUGER-GAUDICHON

Prénom Jérémie

Organisme CHU Caen Normandie

Collaborations

Financements

Gouvernance de la base de données

Organisation(s) responsable(s) ou promoteur CHU Caen Normandie

Statut de l'organisation Secteur Public

Contact(s) supplémentaire(s)

Caractéristiques

Type de base de données

Type de base de données	Study databases
Base de données issues d'enquêtes, précisions	Cohort study
Origine du recrutement des participants	A selection of health institutions and services
Le recrutement dans la base de données s'effectue dans le cadre d'une étude interventionnelle	No
Objectif de la base de données	
Objectif principal	Describe the presentation and clinical course of SARS-CoV-2 infection among patients followed up in a paediatric oncology-haematology department or young adult and adolescent unit at an SFCE centre, for cancer or a benign tumour treated with chemotherapy, radiotherapy or targeted therapy.
Critères d'inclusion	<p>Children and legal representatives, or adult patients having received information on the study AND</p> <ul style="list-style-type: none"> - Patient followed up in a paediatric oncology-haematology department or young adult and adolescent unit at an SFCE centre for cancer or a benign tumour treated with chemotherapy, radiotherapy or targeted therapy, with a cancer treatment either ongoing or completed within the past 6 months, or a history of allogeneic haematopoietic stem cell transplantation with immunosuppressant therapy ongoing or discontinued within the past 6 months, or a history of CAR-T cell therapy <p>AND</p> <ul style="list-style-type: none"> - Diagnosis of SARS-CoV-2 infection confirmed by PCR or positive IgM serology <p>OR</p> <ul style="list-style-type: none"> - Clinical and radiological diagnosis characteristic of SARS-CoV-2 infection without confirmation of infection by PCR or positive IgM serology with: <ul style="list-style-type: none"> o Presence of at least 2 of the following signs in the event of contact with a subject currently presenting SARS-CoV-2 positive infection, or 3 of the following signs in the absence of contact: fever, cough, dysgeusia, dysosmia, myalgia, chest pain, dyspnoea, signs of respiratory distress, rhinorrhoea or nasopharyngeal congestion, diarrhoea, headaches, recent onset or exacerbation of asthenia and rash. <p>AND</p>

- o One or more radiological abnormalities observed on chest CT scan compatible with a diagnosis of COVID-19: peripheral and/or subpleural and/or bilateral ground-glass opacities, intralobular thickening with a “crazy-paving” appearance, linear condensations with or without peripheral halo (reverse halo sign).

Type de population

Age	Newborns (birth to 28 days) Infant (28 days to 2 years) Early childhood (2 to 5 years) Childhood (6 to 13 years) Adolescence (13 to 18 years)
-----	-----------------------------------------------------------------------------------------------------------------------------------------------------------

Population concernée	Sick population
----------------------	-----------------

Pathologie	II - Neoplasms
------------	----------------

Sexe	Male Woman
------	---------------

Champ géographique	National
--------------------	----------

Collecte

Dates

Taille de la base de données

Taille de la base de données (en nombre d'individus)	< 500 individuals
------------------------------------------------------	-------------------

Données

Activité de la base	Current data collection
---------------------	-------------------------

Type de données recueillies	Clinical data Biological data
-----------------------------	----------------------------------

Données cliniques, précisions	Direct physical measures
-------------------------------	--------------------------

Existence d'une biothèque	No
---------------------------	----

Modalités

Pathologie suivies

Valorisation et accès

Valorisation et accès

Accès